Nasvax Advances Most in Three Months on Trial of Liver Treatment
Nasvax shares climbed as much as 8.9 percent, the biggest intraday gain since Dec. 27, to 1.63 shekels. They traded 2.3 percent higher at 1.53 shekels as of 11:24 a.m. in Tel Aviv. Biomedix increased 3.6 percent to 0.607 shekel.
To contact the reporter on this story: Ronit Goodman in Tel Aviv at firstname.lastname@example.org
To contact the editor responsible for this story: Claudia Maedler at email@example.com